Stanford

Jie Liu

Director of Protein Engineering and Molecular Immunology, Stem Cell Bio
Regenerative Med Institute

Publications

PUBLICATIONS

- **MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS).** *Clinical lymphoma, myeloma & leukemia*
  Chen, J., Johnson, L., McKenna, K., Choi, T., Duan, J., Feng, D., Tsai, J., Garcia-Martin, N., Sompalli, K., Maute, R., Vyas, P., Majeti, R., Takimoto, et al
  2022; 22 Suppl 2: S317-S318

- **Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)**
  Chen, J., Johnson, L., McKenna, K., Choi, T., Duan, J., Feng, D., Tsai, J., Garcia-Martin, N., Sompalli, K., Maute, R., Vyas, P., Majeti, R., Takimoto, et al
  CIG MEDIA GROUP, LP.2022: S317-S318

- **Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).**
  Chen, J., Johnson, L., McKenna, K., Choi, T. S., Duan, J., Feng, D., Tsai, J. M., Garcia-Martin, N., Sompalli, K., Maute, R., Vyas, P., Majeti, R., Takimoto, et al
  LIPPINCOTT WILLIAMS & WILKINS.2022

- **NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.** *Blood cancer discovery*
  Richards, R. M., Zhao, F., Freitas, K. A., Parker, K. R., Xu, P., Fan, A., Sotillo, E., Daugaard, M., Oo, H. Z., Liu, J., Hong, W. J., Sorensen, P. H., Chang, et al
  2021; 2 (6): 648-665

- **Targeting macrophage checkpoint inhibitor SIRPa for anticancer therapy.** *JCI insight*
  Liu, J. n., Xavy, S. n., Mihardja, S. n., Chen, S. n., Sompalli, K. n., Feng, D. n., Choi, T. S., Agoram, B. n., Majeti, R. n., Weissman, I. L., Volkmer, J. P.
  2020

- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers** *JOURNAL OF CLINICAL ONCOLOGY*
  Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
  2019; 37 (12): 946-+

- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
  2019: JCO1802018

- **Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.** *Frontiers in oncology*
  Chao, M. P., Takimoto, C. H., Feng, D. D., McKenna, K., Gip, P., Liu, J., Volkmer, J., Weissman, I. L., Majeti, R.
  2019; 9: 1380

- **RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9**
  Chen, J. Y., McKenna, K., Choi, T. S., Duan, J., Brown, L., Stewart, J. J., Sompalli, K., Vyas, P., Schrier, S., Majeti, R., Weissman, I. L., Elrod, K., Chao, et al
  AMER SOC HEMATOLOGY.2018

- **Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia**
  Feng, D., Gip, P., McKenna, K., Zhao, F., Mata, O., Choi, T. S., Duan, J., Sompalli, K., Majeti, R., Weissman, I. L., Takimoto, C. H., Chao, M., Chen, et al
  AMER SOC HEMATOLOGY.2018

- **Programmed cell removal by calreticulin in tissue homeostasis and cancer** *NATURE COMMUNICATIONS*
  Feng, M., Marjon, K. D., Zhu, F., Weissman-Tsukamoto, R., Levett, A., Sullivan, K., Kao, K. S., Markovic, M., Bump, P. A., Jackson, H. M., Choi, T. S., Chen, J., Banuelos, et al
  2018; 9

- **Programmed cell removal by calreticulin in tissue homeostasis and cancer.** *Nature communications*
  Feng, M. n., Marjon, K. D., Zhu, F. n., Weissman-Tsukamoto, R. n., Levett, A. n., Sullivan, K. n., Kao, K. S., Markovic, M. n., Bump, P. A., Jackson, H. M., Choi, T. S., Chen, J. n., Banuelos, et al
  2018; 9 (1): 3194

- **Disrupting the CD47-SIRP alpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors** *SCIENCE TRANSLATIONAL MEDICINE*
  Gholamin, S., Mitra, S. S., Feroze, A. H., Liu, J., Kahn, S. A., Zhang, M., Esparza, R., Richard, C., Ramaswamy, V., Remke, M., Volkmer, A. K., Willingham, S., Ponnuswami, et al
  2017; 9 (381)

- **The CD47 Macrophage Checkpoint as a New Immunotherapy Target**
  Sikic, B. I., Padda, S. K., Shah, S. A., Colevas, D., Narayanan, S., Fisher, G. A., Supan, D., Wakelee, H. A., Aoki, R., Pegram, M. D., Villalobos, V. M., Liu, J., Takimoto, et al
  ELSEVIER SCIENCE INC.2017: S108–S109

- **SIRP alpha-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells** *CLINICAL CANCER RESEARCH*
  Piccione, E. C., Juarez, S., Tseng, S., Liu, J., Stafford, M., Narayanan, C., Wang, L., Weiskopf, K., Majeti, R.
  2016; 22 (20): 5109-5119

- **CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer** *JOURNAL OF CLINICAL INVESTIGATION*
  Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J., Liu, J., Lim, J. S., Yang, D., Seitz, G., Thuyen Nguyen, et al
  2016; 126 (7): 2610-2620

- **A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers**
  Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
  AMER SOC CLINICAL ONCOLOGY.2016

- **Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo** *PLOS ONE*
  Zhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., Liu, J., Achrol, A. S., Richard, C., Sommerkamp, P., Schoen, M. K., McCracken, M. N., Majeti, et al
  2016; 11 (4)

- **A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells** *MABS*
  Piccione, E. C., Juarez, S., Liu, J., Tseng, S., Ryan, C. E., Narayanan, C., Wang, L., Weiskopf, K., Majeti, R.
  2015; 7 (5): 946-956

- **Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.** *PloS one*
  Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., Volkmer, J., Chao, M., Weissman, I. L., Majeti, et al
  2015; 10 (9)

- **OVERCOMING IMMUNE EVASION IN PEDIATRIC BRAIN TUMORS: A PRE-CLINICAL DEVELOPMENT STUDY USING A HUMANIZED ANTI-CD47 ANTIBODY**
  Gholamin, S., Mitra, S., Feroze, A., Zhang, M., Esparza, R., Kahn, S., Richard, C., Achrol, A., Volkmer, A., Liu, J., Volkmer, J., Majeti, R., Weissman, et al
  OXFORD UNIV PRESS INC.2014: 138

- **Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Edris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J., Willingham, S. B., Contreras-Trujillo, H., Liu, J., Majeti, R., West, R. B., Fletcher, J. A., Beck, A. H., Weissman, I. L., van de Rijn, et al
  2012; 109 (17): 6656-6661

- **Effect of nanoparticle size on the aqueous solubility of polymer-coated silver nanoparticles as predicted by the modified Kelvin's equation**

Ma, R., Levard, C., Marinakos, S., Cheng, Y., Liu, J., Michel, F., Brown, G. E., Lowry, G. V.
AMER CHEMICAL SOC.2012